Milestone Pharmaceuticals (MIST) vs Rafael (RFL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Rafael (RFL) has outperformed Milestone Pharmaceuticals (MIST) over the past year, losing 25.8% versus a loss of 84.5%. Over five years, RFL leads with a -84.2% price change compared with -93.8% for MIST. Rafael is the larger company by market cap ($48.0 million vs $46.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MIST | RFL |
|---|---|---|
| Share price | $0.3711 | $0.9197 |
| Market cap | $46.20M | $47.99M |
| 1-day change | -7.06% | +2.19% |
| YTD return | -81.63% | -22.06% |
| 1-year return | -84.54% | -25.83% |
| 5-year return | -93.85% | -84.19% |
| EPS (TTM) | $-0.74 | $-0.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $874.00K |
| Revenue growth (YoY) | — | -4.69% |
| Net income (latest FY) | $-63.06M | $-29.64M |
| Operating margin | — | -3822.54% |
| Net margin | — | -3390.73% |
| 52-week high | $3.06 | $3.96 |
| 52-week low | $0.362 | $0.781 |
| Distance from 52-week high | -87.87% | -76.78% |
| Analyst consensus | none | — |
| Avg. price target upside | +1479.09% | — |
| Average volume | 1.53M | 140.84K |
| Shares outstanding | 124.50M | 51.39M |
| Employees | 38 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RFL has outperformed MIST by 58.7 percentage points over the past year.
About Milestone Pharmaceuticals
MIST stock →Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.
Health Care · Biotechnology: Pharmaceutical Preparations · 38 employees
About Rafael
RFL stock →Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
MIST vs RFL FAQ
Which is bigger, Milestone Pharmaceuticals or Rafael?
Rafael (RFL) is larger, with a market capitalization of $47.99M compared with $46.20M for Milestone Pharmaceuticals (MIST).
Which stock has performed better over the past year, MIST or RFL?
RFL returned -25.83% over the past 12 months, compared with -84.54% for MIST (price return, excluding dividends). Past performance does not predict future results.
Are Milestone Pharmaceuticals and Rafael in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.